- VISITING ASSOCIATE PROFESSOR Psychiatry
Dr. Pallanti's clinical interests include:
Clinical rTMS for treatment of auditory hallucination, bipolar mood disorders, depression, resistant OCD
Impulse Control disorder
ResearchDr. Pallanti's most recent interested is Clinical Transcranial Magnetic Stimulation (rTMS / deep TMS ) in adult and young adult with Resistant disorders,Depression Bipolar nd Psychotic disorders including Schizophrenia spectrum, Prodromal, early Onset, treatment of Resistant Hallucination, treatment of Negative and Cognitive Symptoms in Schizophrenia and treatment of Resistant OCD-Impulsive Spectrum Disorder, including Autism Spectrum Disorder. Anxiety, OCD spectrum disorders including Pathological Gambling and other Behavioral Addiction and Impulse Control.
Dr. Pallanti's role within the Department of Psychiatry has included organizing and directing Mount Sinai's Center of Excellence for OCD, impulsive, and behavioral addiction. Under his leadership as Director, the Center broke into new ground with its cutting-edge approaches to treatment and an innovative blend of therapeutic programs, research and educational activities.
Google scholar: http://scholar.google.com/citations?user=OTodZXQAAAAJ&hl=en
Pallanti S, Grassi G, Cantisani A. Emerging drugs to treat obsessive-compulsive disorder. Expert Opinion, Informa UK, Ltd;.
Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in patients with Obsessive-Compulsive Disorder who are inadequate responders to serotonin reuptake inhibitors: Improvement with treatment and worsening following discontinuation. European Neuropsychopharmacology 2013;.
Pallanti S, Grassi G, Antonini S, Quercioli L, Salvadori E, Hollander E. rTMS in resistant mixed states: An exploratory study. Journal of Affective Disorders 2013;.
Marras A, Pallanti S. Transcranial magnetic stimulation for the treatment of pharmacoresistant nondelusional auditory verbal hallucinations in dementia. Case reports in psychiatry 2013; 2013.
Grassi G, Poli L, Cantisani A, Righi L, Ferrari G, Pallanti S. Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. CNS spectrums 2013 Nov;.
Pallanti S, Hollander E. Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity. CNS spectrums 2013 Nov;.
Pedrosa AK, Pinto FJ, Lins LD, Deus GM. Blood transfusion reactions in children: associated factors. Jornal de pediatria; 89(4).
Pallanti S, Cantisani A, Grassi G. Anxiety as a core aspect of schizophrenia. Current psychiatry reports 2013 May; 15(5).
Baldwin DS, Pallanti S, Zwanzger P. Developing a European research network to address unmet needs in anxiety disorders. Neuroscience and biobehavioral reviews 2013 Dec; 37(10 Pt 1).
Bandinelli F, Prignano F, Bonciani D, Pallanti S, Lotti T, Salaffi F, Bartoli F, Candelieri A, Giovannini L, Maddali Bongi S, Matucci-Cerinic M. Clinical and demographic factors influence on anxiety and depression in early psoriatic arthritis (ePsA). Clinical and experimental rheumatology; 31(2).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Pallanti is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Istituto di Neuroscienze
Via A. Lamarmora 24
Florence ITALY, -- 50121